SciELO - Scientific Electronic Library Online

vol.46 issue3Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasRat vas deferens SERCA2 is modulated by Ca2+/calmodulin protein kinase II-mediated phosphorylation author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Brazilian Journal of Medical and Biological Research

On-line version ISSN 1414-431X

Braz J Med Biol Res vol.46 no.3 Ribeirão Preto Mar. 2013  Epub Mar 15, 2013 


Impact of HPV infection on the development of head and neck cancer

J. Betiol1 

L.L. Villa1  2  3 

L. Sichero1 

1Instituto do Câncer do Estado de São Paulo, Laboratório de Biologia Molecular, Centro de Investigação Translacional em Oncologia, São Paulo, SP, Brasil

2Universidade de São Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina, São Paulo, SP, Brasil

3Santa Casa de Misericórdia de São Paulo, Instituto do HPV , São Paulo, SP, Brasil


Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) is considered to be a distinct clinical entity with better prognosis than the classical tobacco- and alcohol-associated tumors. The increasing incidence of this neoplasia during the last decades highlights the need to better understand the role of HPV in the development of these cancers. Although the proportion of HNSCC attributed to HPV varies considerably according to anatomical site, overall approximately 25% of all HNSCC are HPV-DNA positive, and HPV-16 is by far the most prevalent type. In this review we discuss the existing evidence for a causal association between HPV infection and HNSCC at diverse anatomical head and neck subsites.

Key words: Human papillomavirus; Oncogenic potential; Head and neck cancer; Viral prevalence

Human papillomavirus


The Papillomaviridae family is a diverse group of small non-enveloped tumor viruses that infect, in a species-specific way, the mucosal and cutaneous epithelia of a broad variety of higher vertebrates. The human papillomavirus (HPV) virion is approximately 55 nm in diameter and encloses a single-closed circular double-stranded DNA genome of about 8000 bp bound to cellular histones. The viral genome encodes approximately eight open-reading frames that can be functionally divided into three parts: the early (E) region that encodes proteins necessary for viral replication and transcription, the late (L) region that encodes the structural proteins of the capsid (L1 and L2), and a non-coding region segment designated long control region (LCR), which contains cis-elements necessary for viral DNA replication and transcription regulation 1.


HPV presents specificity for different tissues and diverse distribution among different anatomical sites. The majority of HPV genotypes belong to three different genera: α-papillomavirus, predominantly isolated from genital lesions, β-papillomavirus, referred to as HPV related to Epidermiodisplasia verruciforme, and γ-papillomavirus. β- and γ-papillomaviruses have been mainly isolated from cutaneous lesions 2.

In humans, over 150 different HPV genotypes have been fully sequenced and numbered in the order of their discovery 3. HPV taxonomy is based on L1 sequence variability: viral genomes are classified as new types when they present less than 90% of identity to any other type. Differences in identity of less than 2% within the L1 late gene define molecular variants of HPV 2. Nevertheless, nucleotide variability among variants differs across viral genes and can be as high as 5% in the LCR. Mostly, viral variants arise by nucleotide substitutions in few restricted positions within the entire genome. Nucleotide sequence analysis of HPV-16- and -18-positive cervical samples collected worldwide has categorized molecular variants into phylogenetically related lineages: European, Asian-American, Asian, and African 4. More recently, the nomenclature of variant lineages has been established for other HPV types 5,6. Distribution of HPV-16 and -18 molecular variants varies significantly among different geographical areas and correlates with the intrinsic level of admixture of each population.

Approximately 40 viral types infect the anogenital mucosa and HPVs have been further categorized as high- and low-risk types based on the risk of the virus to cause squamous cell carcinomas in the uterine cervix. α-papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 have been classified by the World Health Organization as carcinogenic in humans (carcinogens type I) due to their high prevalence in cervical cancer samples 7. In contrast, infections by non-oncogenic or low-risk HPV types 6, 11, 40, 42, 43, 44, and 54 are associated with the development of genital warts 8.

Oncogenic potential

The role of HPV in cervical carcinogenesis has been widely studied and documented. HPVs specifically target the undifferentiated proliferative basal cells of the epithelial mucosa exposed after tissue trauma. The virus further establishes productive infections within the stratified epithelia in such a way that the viral life cycle is closely linked to the differentiation program of the infected epithelial cell 1.

The HPV genome region sufficient for primary human keratinocyte immortalization maps to the LCR and E6/E7 early genes 9. Transcription is regulated in a complex manner based on the identity of the infected epithelial cell type, the differentiation status of the stratified epithelium, and the episomal or chromosomally integrated state of the viral genome 10. HPV expression is regulated by cellular and viral transcription factors that bind to specific elements within the LCR, which varies widely among different HPV types. The E2 early regulatory protein binds to four different conserved sites in the LCR and inhibits E6and E7 transcription 11. Yet, in tumor cells, viral genomes are frequently integrated into the host DNA, with interruption of the E2 gene leading to an elevated expression of the E6 and E7 oncogenes.

High-risk HPV E6 and E7 proteins cooperate in the immortalization of primary human keratinocytes and in the inhibition of the differentiation of these cells induced by serum and calcium 12. These proteins bind with different affinity to host cell proteins and disturb the normal epithelial differentiation and apoptosis by stimulating cellular proliferation, DNA synthesis and inhibition of cell cycle control 1. The best-studied interactions are the association and degradation of TP53 and pRB by E6 and E7, respectively 13,14. TP53 mediates cell cycle arrest by blocking the progression at the G1/S checkpoint and E6-induced TP53 degradation abolishes this control. Additionally, high-risk HPV E6 stimulates cell proliferation by interacting with PDZ proteins including MUPP-1, hSCRIB and hDlg 15, and increases the lifespan of infected cells through the activation of telomerase 16. Functional inactivation of the pRB protein family by high-risk HPV E7 results in the release of the E2F transcription factor and further upregulation of cell cycle genes 1. In this way, high-risk HPV E7 activates DNA synthesis and cell replication mechanisms normally inactive in matured epithelial cells, initiating pathological cell growth. E6 complements E7 function by inducing cell survival and delayed apoptosis and together they mediate HPV-associated epithelial cell immortalization and cellular genomic instability that stimulates infected cells to assume a fully malignant phenotype.


HPV is one of the most common sexually transmitted infections. It is the cause of a number of neoplasias, including cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers. Additionally, genital warts and the rare but very serious recurrent respiratory papillomatosis are etiologically associated with this virus 17.

HPV-induced cervical carcinogenesis is the most extensively studied malignancy associated with this virus. Infection of the uterine cervix is linked to high-risk sexual behavior including number of sex partners and age at first sexual intercourse. Other important co-factors for malignant clinical outcome include immune and nutritional status, the use of tobacco, and co-infection with other sexually transmitted agents including HIV and Chlamydia trachomatis 18.

Persistent infection with high-risk HPVs is responsible for the development of most, if not all, cervical cancers worldwide 19. Among these, HPV-16 is undoubtedly the most prevalent and, together with HPV-18, accounts for approximately 70% of all cervical cancer cases 20. Besides persistence of infection, the HPV type detected, the presence of multiple HPVs, whether the viral DNA is present episomally or integrated and viral load influence the development of cervical cancer.

Head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) comprises tumors of diverse origin, which are further categorized by the anatomical sub-site in which they emerge. Most HNSCC arise in the oral cavity, the oropharynx or the larynx. Nevertheless, in some epidemiological studies, HNSCC has been frequently treated as a single disease and not stratified according to the anatomical region affected. Grouped together, oral and pharyngeal cancers are the sixth most common neoplasias in the world 21. In Europe 67,354 new cases of oral, pharyngeal, and laryngeal cancers are estimated to occur in men every year 22, while in the United States 52,610 new cases were expected for 2012 23. Additionally, in Brazil, 20,280 new cases of oral and laryngeal cancer were expected for 2012 24. Worldwide, the incidence of cancer at different head and neck sites varies by geographical region. A higher prevalence of HNSCC was reported among non-Hispanic Black men aged less than 55 years 25,26. The most important risk factors associated with HNSCC development include tobacco and alcohol use, with a synergistic effect between them 27. Nevertheless, at least a fraction of oral and pharyngeal cancers cannot be attributed to these factors. In the United States it was observed that tobacco smoking and alcohol drinking combined account for approximately 75% of all oral and pharyngeal cancers 28. The remaining 25% of affected individuals require further analysis 29. Among never smoker and never drinker (NSND) patients, the incidence of HNSCC at different anatomical subsites was shown to segregate by sex and age. It was observed that in NSND individuals, the oropharynx was the most common site of tumor occurrence. However, gender-specific differences were reported. In young to middle-aged men, tumors of the oropharynx accounted for more than half of all HNSCC. In contrast, these occurred in only 21% of NSND women under 50 years of age, in which oral tongue cancer was more commonly detected 30.

Association with HPV infection

Similarities in morphological features between genital and oral HPV-associated lesions have suggested that HPV infection could be an additional risk factor in a subset of oral cancers. For instance, the juxtaposition between the squamous cell epithelium and the lymphatic tissue in the oropharynx resembles the transformation zone of the uterine cervix, and may thus be susceptible to HPV infection. Actually, the first report suggestive of the viral etiology of oral squamous-cell carcinoma (OSCC) dates to 1983 when microscopic changes suggestive of HPV infection were detected in 40% (16/40) of the cases 31. Since then, evidence for a link between HPV infection and HNSCC development has been growing.

Strong and consistent molecular evidence demonstrating that HPV is an important etiological cause of HNSCC is based on: 1) frequent detection of HPV genomic sequences and transcription of E6 and E7 genes in tumor cells; 2) HPV-DNA integration in the cellular genome of tumor cells; 3) existence of a considerable viral DNA copy number in these lesions 32. In addition, serum antibodies against HPV-16 L1, E6, and E7 proteins were detected in over 60% of individuals diagnosed with oropharyngeal squamous cell carcinoma 33. Further experimental evidence involving HPV in a subset of oropharyngeal cancers was provided by the observation thatE6 and E7 oncogene silencing induces apoptosis and restoration of TP53 and pRB tumor suppressor pathways in oropharyngeal cancer cells 34. For these reasons, during the last decade, molecular and epidemiological investigations have focused on HPV-associated HNSSC 33,35,36.

The incidence of HPV-associated HNSCC is increasing in young adults, a fact that may be explained, at least in part, by changes in sexual behavior 37. HPV infection of the oropharynx like HPV infection of the uterine cervix was shown to be associated with high-risk sexual behavior. In particular, some studies have indicated that orogenital sex is a potentially risk-related sexual practice 33. Additionally, the risk of developing HPV-associated HNSCC is increased in men and women with multiple sex partners and in men with a history of anogenital warts. It was also observed that husbands of women with cervical cancer are predisposed to develop HPV-associated HNSCC, especially tonsillar cancer 38. Furthermore, other risk factors have been consistently linked to an increased chance of prevalent oral HPV infection. Current smoking and HIV infection were both associated with significantly augmented oral HPV prevalence, suggesting that tobacco-related and HIV-related immunosuppression may possibly impact the natural history of oral HPV 39. However, patients diagnosed with HPV-positive HNSCC tend to be younger and to have a lower intake of tobacco and alcohol 40.

Detection rates of HPV-DNA in HNSCC are highly variable (Figure 1). The remarkable variation in viral prevalence among different reported studies may be due to grouping together lesions at different anatomical subsites, to small sample numbers, to the ethno-geographical origins of the subjects examined, and to differences in sampling techniques (frozen, formalin-fixed or paraffin-embedded sections, scraping or oral rinses) 41. Considering all anatomical head and neck subsites, the rate of HPV detection is usually higher in frozen biopsy samples than in formalin-fixed samples 7. In addition, the methodologies used may influence the viral prevalence measured in these samples, and for this reason rigorous criteria should be considered, such as sensitivity/limit of detection, specificity (including HPV types and variants), accuracy, and reproducibility42. A significant increase in HPV detection rate was observed using an auto-nested GP5+/GP6+ protocol compared to single-PCR assays among oral mucosal samples, but not among cervical specimens43.

Figure 1 Overall HPV-DNA prevalence in head and neck squamous cell carcinomas at different anatomical subsites. Range values stratified by geographical location are shown in parentheses (Ref. 45). 

While HPV is an important cause of oropharyngeal cancer, it is presently uncertain whether it may also have a role in cancer of other head and neck subsites. HPV-DNA has been detected in a subset of oral cavity (23%) and larynx (24%) tumors, although the proportion of these neoplasias that are HPV positive is markedly inferior to that observed for oropharyngeal cancer (50%) 44,45. Although HPV-16 is by far the most prevalent type detected in these tumors, a recent analysis of oral rinse samples revealed a wide spectrum of HPV types from the 3 main genera (α-, β- and γ-papillomavirus) 46. Among 317 male individuals, 168 type-specific infections were detected of which 64 and 8.3% were β- and γ-papillomavirus, respectively. Types from these genera were previously considered to be exclusively cutaneous. The finding that HPV infection is linked to the development of a subset of HNSCC has prompted new interest in a better understanding of the natural history of HPV infections in the different head and neck anatomical subsites.

Recurrent respiratory papillomatosis

Low-risk HPV-6 and -11 infections within the larynx can lead to the development of recurrent respiratory papillomatosis (RRP). This neoplasia is very uncommon and is characterized by multiple benign papillomas in the middle and lower respiratory tract 47. Despite its benign nature, RRP can involve considerably morbidity and mortality since lesions tend to grow and cause severe air obstruction. RRP exhibits a bimodal age distribution: the first peak of incidence occurs before 5 years of age and the second peak between the ages of 20 and 30 years. Boys and girls are evenly affected by juvenile onset RRP, in contrast to adult onset RRP, which preferentially affects men over women at a ratio of approximately 3:2 48. Vertical transmission for the juvenile RRP form is the most likely route of transmission, whereas adult patients may have been exposed during sexual contact.

Although RRP is generally considered to be histologically benign, its natural history is highly variable and unpredictable and may further undergo malignant transformation. While extralaryngeal and pulmonary spread of RRP has been reported, malignant transformation of RRP is a very rare condition 49. Furthermore, HPV-11-associated RRP was observed to be more prone to malignant transformation as compared to HPV-6-associated disease 50. It is still unclear why only a fraction of HPV-exposed individuals develop RRP, and why among HPV-associated RRP cases, only a few develop cancer. The detection of serum antibodies to HPV among RRP patients refutes the hypothesis that these infections may be ignored by the immune system 51; most likely these individuals develop tolerance to HPV infection to different extents. The main determining factor proposed for RRP clinical outcome could be HPV-specific TH1-/TH2-like balance polarization. Although a considerable amount of information is available concerning the immunological aspects of HPV-induced RRP, lesion recurrence and malignization 52, more data are required and will prove important to the development of therapies that may prevent not only lesion development and recurrence, but also malignant transformation.

Oral cancer

Oral cancer includes tumors of the tongue, floor of the mouth, gum, palate, and other mouth subsites. From the mid-1970s to the latest Surveillance Epidemiology and End Results Program (SEER Program) from the U.S. National Cancer Institute Survey performed in 2004, oral cancer rates have increased by approximately 15%53. Recent data from the SEER Program have revealed a higher incidence of this neoplasia among men (15.5 per 100,000 per year) and among Hispanic (9.2 per 100,000 per year) and Black (17.2 per 100,000 per year) individuals 54. Increased rates of oral cancer are also associated with age, starting after 50 years and peaking between 60 and 70 years. Generally, the highest rates of oral cancer are detected in Melanesia, South Central Asia, and Central and Eastern Europe, and the lowest rates in Africa, Central America and Eastern Asia 55. The most common histological type of oral cancer is OSCC 56.

In OSCC, as for the majority of HNSCC, higher tobacco and alcohol consumption constitutes the most important risk factor although 10 to 20% of the individuals diagnosed with OSCC have no history of being exposed to these agents 56. Indeed, other biological factors have been proposed to play a role in oral carcinogenesis 57,58. Based on epidemiological and clinico-pathological evidence, HPV infection has been proposed to be linked to oral cancer development 59,60. Nevertheless it is important to emphasize the weaker etiological association between HPV infection and oral cancer as compared to oropharynx cancer 44. Concerning cancer samples, the evaluation of 209 cases of oral cavity carcinomas obtained from a Hospital database in France revealed a 10.5% prevalence of HPV, with viral detection being more common among females (17.2%) than among males (8.0%) 61. On the other hand, in a multicenter study (Japan, Pakistan, and Colombia) 56% of HPV positivity was detected among 71 samples of oral cavity cancers, with HPV-16 being the most prevalent type 62. In these three countries, HPV prevalence did not vary significantly by geographical region. However, it was observed that molecular variants of HPV-16 were unevenly distributed in these samples. A meta-analysis compiling 35 studies from 24 different countries revealed an overall HPV prevalence of 23.5% among 2642 OSCC cases 45. In these tumors HPV-16 was also the most prevalent viral type (68%), followed by HPV-18 (8%). However, among 409 OSCC cases diagnosed in North American Hospitals, only 5.9% could be attributed to HPV infection 63. The divergent records obtained in the different studies reported may be explained by differences in the socioeconomic conditions of the populations analyzed, the prevalence of other risk factors, the biological samples analyzed, and the methods used for HPV detection.

HPV has been also detected in the oral cavity of healthy individuals. Among 5579 individuals aged 14 to 69 years randomly investigated in the United States who underwent an oral rinse, the overall HPV prevalence observed was 6.9% 64. Moreover, in that cohort viral DNA was more commonly detected among men than women (10.1 versus 3.6%). In a multinational sample cohort, HPV infection was detected in 4% of 1688 healthy men aged 18 to 74 years enrolled in the United States, Mexico, and Brazil 65. Although HPV-16 was also the most frequently detected high-risk HPV type in all cohorts, HPV-55 was more common in Mexico. The significance of HPV infection in healthy oral mucosa is not fully understood although reported data indicate that the development of OSCC is associated with the practice of orogenital sex and with high-risk sexual behavior 66. In addition, tobacco smoking and increased age were found to be associated with a higher frequency of persistent oral HPV infections 33. Studies are warranted to elucidate the natural history and epidemiology of oral HPV infections.

Pharyngeal cancer

Pharyngeal tumors include cancer of the hypopharynx, nasopharynx, oropharynx, and tonsils. According to The French National Hospital Database (PMSI), 36,268 patients were hospitalized for head and neck cancer in France in 2007, and tumors were more frequently detected in the oropharynx among these individuals (n = 12,232) 67. These tumors were more frequently detected among men. Cancers of the oropharynx and tonsils are also associated with tobacco and alcohol consumption 68. However, consistent epidemiological evidence has been extensively obtained over the last decade concerning HPV-associated pharyngeal cancer. The highest incidence of HPV infection among laryngeal squamous cell carcinoma maps to the oropharynx. It was observed that HPV-related squamous cell carcinoma of the oropharynx has unique histological features 69,70; these tumors tend to present a non-keratinizing basaloid morphology and an increased expression of p16 and Ki67. In contrast, non-HPV-related tumors are keratinizing and are composed of polygonal cells with abundant mature cytoplasm.

The French National Hospital Database reports an overall HPV prevalence ranging from 33 to 72% among oropharyngeal cancers in different French public and private hospitals 61. Worldwide, HPV prevalence has been shown to vary from 14 to 57% in cancers of the oropharynx7,45. However, a lower prevalence was reported in two large case-control studies conducted in Central Europe and Latin America in which HPV prevalence was 4.4% among oropharynx cancers and 3.8% among hypopharynx/larynx cancers 71. Among tonsillar carcinomas, HPV-DNA was detected in 52% of affected individuals 72.

In common, all studies reported that high-risk HPV-16 was undoubtedly the predominant viral type detected. Viral oropharyngeal infection has also been shown to be more common among younger subjects with high-risk sexual behavior. These individuals present higher serum HPV-16 antibody titers, use less tobacco and alcohol, and have a better survival rate compared to HPV-negative tumors73. In addition, it was reported that detection of HPV-16 DNA in oral exfoliated cells increased the odds of oropharyngeal cancer by more than 14-fold 33.

Laryngeal cancer

Laryngeal carcinoma is the second most common malignancy of the head and neck74. According to the global cancer statistics of 2008, the age-standardized incidence rate of this malignancy is 5.5 per 100,000 per year in men and 0.6 per 100,000 per year in women in developed areas, while in less developed areas, the incidence rate is 3.5 per 100,000 in men and 0.6 per 100,000 in women 75. In Brazil, 6110 new cases of laryngeal cancer are expected to be diagnosed in men in 2012, while no data are available for women due to the small number of females affected by this cancer in Brazil 24.

Tobacco and alcohol consumption are the primary etiologic factors for the development of laryngeal cancer. The laryngeal epithelium is known to be susceptible to HPV infection because of the well-established association of HPV-6 and -11 infections with the development of juvenile and adult onset RRP. Recently, it was suggested that HPV infection may also account for the development of a fraction of laryngeal carcinomas 76. HPV prevalence varies from 5 to 24% among larynx cancers in different public and private hospitals in France 67. In addition, a systematic analysis of 35 studies from 18 different countries involving a total of 1435 cases of larynx cancer revealed an overall HPV prevalence of 24% 45. However, as for all other HNSCC subsites, a high divergence in HPV prevalence has been reported, ranging from 16.5 to 41.5% 46,77. Nevertheless, the associations described are not as significant as documented for the tonsils and the oropharynx 78.

Future directions

HPV infection is one of the most common sexually acquired diseases. Head and neck HPV infections have not been studied to the same extent as infections of the genital tract. However, in 2007 the International Agency for Research on Cancer (IARC) concluded that there was sufficient evidence to support the carcinogenicity of HPV in the oral cavity, oropharynx and tonsils, and limited evidence to support the carcinogenicity of HPV in the larynx 7.

To date, limited information is available about the natural history of oral HPV infection. More longitudinal research is needed to better understand the transmission of oral HPV infections, how likely these infections are to clear and what factors are associated with persistence. This should prove important since HPV persistence is a necessary cause of cervical cancer development and may likely prove central for HPV-associated HNSCC.

Most studies conducted thus far have detected predominantly HPV-16 among cancer samples in all head and neck subsites 45,79,80. Significant differences in pathogenicity exist between molecular variants of a single type and have been elucidated most clearly for HPV-16 4. It has been demonstrated that non-European variants of HPV-16 are more strongly associated with cancer development when compared to European variants. Furthermore, non-European variants are more prevalent in cancer samples than in normal smears. While most of the studies analyzing specific HPV variants regarding the risk for viral persistence and cancer development have been performed in cervical cancer 81,82, very few studies of this kind have been conducted in head and neck samples. In the United States, a striking similarity has been observed in the distribution of the different HPV-16 variants in HNSCC and in cervical cancers 83. In addition, the prognostic significance of HPV-16 E6 variants in HNSCC was evaluated in two recent studies84,85. Nevertheless, HPV molecular variant analysis should be more extensively investigated in HNSCC before proving to impact lesion outcome.

Another important aspect concerns the remarkable discrepancy in documented HPV prevalence in different anatomical HNSCC subsites across studies. Thus, not only standardization of the techniques employed for HPV diagnosis and typing but also separation of samples from the diverse head and neck anatomical subsites are essential for comparing data from different geographical areas. Albeit it is not always possible to unmistakably identify the exact anatomical site of the primary tumor, anatomical site misclassification may further introduce variation in the estimate of HPV prevalence. Overall, HPV-positive HNSCCs have been shown to have a better clinical outcome than HPV-negative cases 86. A meta-analysis revealed that individuals with HPV-positive HNSCC had lower risk of dying and of recurrence especially when analysis was restricted to HPV-positive oropharyngeal cancers 87,88. It was also observed that these patients respond better to chemotherapy and radiotherapy than HPV-negative individuals 89. Additionally, the prognostic value of tumor stage was shown to be significant only among HPV-positive tonsillar cancers 90. However, not all studies show consistent results and the prognostic value of HPV remains uncertain especially among OSCC. It was observed that HPV-16-positive individuals with advanced OSCC had a poor survival rate and were at higher risk of developing distant metastases compared to HPV-16-negative cases 91.

More recently it was suggested that HPV-DNA status in HNSCC should be analyzed together with specific markers of active infection (for instance, E6/E7 mRNA transcription, cellular p16 expression) so as to better define the fraction of these tumors that can be attributable to HPV. HPV status is not always associated with p16 expression, and E6/E7 mRNA and p16 expression was detected mostly in oropharyngeal cancers 59. In fact, HPV-positive patients with oropharyngeal SSC expressing high levels of p16 were shown to have the highest rates of overall survival and disease-free survival 92. In addition, p16 expression had a major impact on the response to treatment 93, and it was suggested that individuals with HPV-DNA-positive/p16-negative oropharyngeal SCC may be treated as HPV negative for clinical purposes 94. However, more research is warranted before establishing the use of HPV status to guide treatment and to predict the outcome of HNSCC.

Prophylactic HPV vaccines are currently available. Clinical trials have demonstrated high efficacy of the vaccine for the prevention of anal, cervical, vaginal, and vulvar cancer development among individuals not previously exposed to HPV 95. Vaccination induces not only a vigorous immune response but also a B-cell immune memory response that persists for years. Direct evaluation of vaccine efficacy against head and neck HPV-16 infection and tumor development is still necessary because there are no published data on this topic. The introduction of HPV vaccination as a public health measure against anogenital HPV infection will most probably also have a favorable impact on the frequency of HPV-mediated HNSCC.


Research supported by FAPESP (grant #12/01513-9 to J. Betiol and grants #11/09616-9 and #08/57889-3 to L.L. Villa) and CNPq (grant #573799/2008-3 to L.L. Villa).


1. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-372, doi: 10.1128/MMBR.68.2.362-372.2004. [ Links ]

2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27, doi: 10.1016/j.virol.2004.03.033. [ Links ]

3. van Doorslaer K, Bernard HU, Chen Z, de Villiers EM, zur Hausen H, Burk RD. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol 2011; 19: 49-50, doi: 10.1016/j.tim.2010.11.004. [ Links ]

4. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006; 39: 707-717, doi: 10.1590/S0100-879X2006000600002. [ Links ]

5. Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, et al. Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. Acta Dermatovenerol Alp Panonica Adriat 2011; 20: 113-123. [ Links ]

6. Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011; 6: e20183, doi: 10.1371/journal.pone.0020183. [ Links ]

7. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636. [ Links ]

8. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8, doi: 10.1186/1750-9378-4-8. [ Links ]

9. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 1991; 181: 374-377, doi: 10.1016/0042-6822(91)90507-8. [ Links ]

10. O'Connor MJ, Stunkel W, Koh CH, Zimmermann H, Bernard HU. The differentiation-specific factor CDP/Cut represses transcription and replication of human papillomaviruses through a conserved silencing element. J Virol 2000; 74: 401-410, doi: 10.1128/JVI.74.1.401-410.2000. [ Links ]

11. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A 1992; 89: 3159-3163, doi: 10.1073/pnas.89.7.3159. [ Links ]

12. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-3910. [ Links ]

13. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-4105. [ Links ]

14. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505, doi: 10.1016/0092-8674(93)90384-3. [ Links ]

15. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010; 118: 471-493, doi: 10.1111/j.1600-0463.2010.02618.x. [ Links ]

16. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82, doi: 10.1038/380079a0. [ Links ]

17. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009; 10: 321-322, doi: 10.1016/S1470-2045(09)70096-8. [ Links ]

18. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, et al.Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431-439, doi: 10.1002/ijc.20257. [ Links ]

19. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-1799, doi: 10.1086/657321. [ Links ]

20. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-105, doi: 10.1038/sj.bjc.6601024. [ Links ]

21. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-316, doi: 10.1016/j.oraloncology.2008.06.002. [ Links ]

22. Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsague X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012; 12: 30, doi: 10.1186/1471-2407-12-30. [ Links ]

23. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012. [ Links ]

24. INCA (Instituto Nacional do Câncer). Estimativa 2012: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2011. [ Links ]

25. Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 2010; 116: 2635-2644. [ Links ]

26. Cole L, Polfus L, Peters ES. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the US, 1995-2005. PLoS One 2012; 7: e32657, doi: 10.1371/journal.pone.0032657. [ Links ]

27. Castellsague X, Quintana MJ, Martinez MC, Nieto A, Sanchez MJ, Juan A, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer 2004; 108: 741-749, doi: 10.1002/ijc.11627. [ Links ]

28. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-3287. [ Links ]

29. Kruse AL, Bredell M, Gratz KW. Oral squamous cell carcinoma in non-smoking and non-drinking patients. Head Neck Oncol 2010; 2: 24, doi: 10.1186/1758-3284-2-24. [ Links ]

30. Dahlstrom KR, Little JA, Zafereo ME, Lung M, Wei Q, Sturgis EM. Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck 2008; 30: 75-84, doi: 10.1002/hed.20664. [ Links ]

31. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12: 418-424, doi: 10.1016/S0300-9785(83)80033-7. [ Links ]

32. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489, doi: 10.1016/S0140-6736(04)16194-1. [ Links ]

33. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956, doi: 10.1056/NEJMoa065497. [ Links ]

34. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010; 8: 433-443, doi: 10.1158/1541-7786.MCR-09-0345. [ Links ]

35. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 2001; 13: 183-188, doi: 10.1097/00001622-200105000-00009. [ Links ]

36. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, et al. Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 2011; 268: 1541-1547, doi: 10.1007/s00405-011-1714-8. [ Links ]

37. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-789, doi: 10.1016/S1470-2045(10)70017-6. [ Links ]

38. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev 2000; 9: 433-437, doi: 10.1097/00008469-200012000-00010. [ Links ]

39. Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol 2012; 33: 130-136, doi: 10.1016/j.amjoto.2011.02.001. [ Links ]

40. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420, doi: 10.1093/jnci/djn025. [ Links ]

41. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, et al. HPV in oral squamous cell carcinoma versus head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008; 19: 1681-1690, doi: 10.1093/annonc/mdn372. [ Links ]

42. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared within situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221, doi: 10.1200/JCO.2009.23.1670. [ Links ]

43. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kuhndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 2004; 30: 302-308, doi: 10.1016/j.jcv.2003.12.011. [ Links ]

44. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 259-266, doi: 10.1111/j.1749-4486.2006.01246.x. [ Links ]

45. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475, doi: 10.1158/1055-9965.EPI-04-0551. [ Links ]

46. Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, Sun C, et al. The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 2011; 204: 787-792, doi: 10.1093/infdis/jir383. [ Links ]

47. Katsenos S, Becker HD. Recurrent respiratory papillomatosis: a rare chronic disease, difficult to treat, with potential to lung cancer transformation: apropos of two cases and a brief literature review. Case Rep Oncol 2011; 4: 162-171, doi: 10.1159/000327094. [ Links ]

48. Shykhon M, Kuo M, Pearman K. Recurrent respiratory papillomatosis. Clin Otolaryngol Allied Sci 2002; 27: 237-243, doi: 10.1046/j.1365-2273.2002.00555.x. [ Links ]

49. Silver RD, Rimell FL, Adams GL, Derkay CS, Hester R. Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 2003; 129: 622-629, doi: 10.1016/j.otohns.2003.08.018. [ Links ]

50. Gelinas JF, Manoukian J, Cote A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol 2008; 72: 433-452, doi: 10.1016/j.ijporl.2007.12.003. [ Links ]

51. Bonnez W, Kashima HK, Leventhal B, Mounts P, Rose RC, Reichman RC, et al. Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology 1992; 188: 384-387, doi: 10.1016/0042-6822(92)90770-P. [ Links ]

52. Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010; 118: 455-470, doi: 10.1111/j.1600-0463.2010.02617.x. [ Links ]

53. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (2000-2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. [ Links ]

54. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute; 2009. [ Links ]

55. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90, doi: 10.3322/caac.20107. [ Links ]

56. Bertolus C, Goudot P, Gessain A, Berthet N. Clinical relevance of systematic human papillomavirus (HPV) diagnosis in oral squamous cell carcinoma. Infect Agent Cancer 2012; 7: 13, doi: 10.1186/1750-9378-7-13. [ Links ]

57. Jiang R, Gu X, Moore-Medlin TN, Nathan CA, Hutt-Fletcher LM. Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19. Oral Oncol 2012; 48: 836-841, doi: 10.1016/j.oraloncology.2012.03.017. [ Links ]

58. Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10: 132-137, doi: 10.1007/s12663-011-0195-z. [ Links ]

59. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-F54, doi: 10.1016/j.vaccine.2012.05.070. [ Links ]

60. Kreimer AR, Bhatia RK, Messeguer AL, Gonzalez P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-391. [ Links ]

61. St Guily JL, Jacquard AC, Pretet JL, Haesebaert J, Beby-Defaux A, Clavel C, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France - The EDiTH VI study. J Clin Virol 2011; 51: 100-104, doi: 10.1016/j.jcv.2011.03.003. [ Links ]

62. Castillo A, Koriyama C, Higashi M, Anwar M, Bukhari MH, Carrascal E, et al. Human papillomavirus in upper digestive tract tumors from three countries. World J Gastroenterol 2011; 17: 5295-5304, doi: 10.3748/wjg.v17.i48.5295. [ Links ]

63. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 2013; 49: 1-8, doi: 10.1016/j.oraloncology.2012.07.002. [ Links ]

64. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703, doi: 10.1001/jama.2012.101. [ Links ]

65. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev 2011; 20: 172-182, doi: 10.1158/1055-9965.EPI-10-0682. [ Links ]

66. Syrjanen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007; 356: 1993-1995, doi: 10.1056/NEJMe078004. [ Links ]

67. St Guily JL, Borget I, Vainchtock A, Remy V, Takizawa C. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010; 2: 22, doi: 10.1186/1758-3284-2-22. [ Links ]

68. Rodriguez T, Altieri A, Chatenoud L, Gallus S, Bosetti C, Negri E, et al. Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol 2004; 40: 207-213, doi: 10.1016/j.oraloncology.2003.08.014. [ Links ]

69. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009; 3: 186-194, doi: 10.1007/s12105-009-0126-1. [ Links ]

70. El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 339-345, doi: 10.1016/j.tripleo.2005.08.001. [ Links ]

71. Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011; 40: 489-502, doi: 10.1093/ije/dyq249. [ Links ]

72. Hannisdal K, Schjolberg A, De Angelis PM, Boysen M, Clausen OP. Human papillomavirus (HPV)-positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol 2010; 130: 293-299, doi: 10.3109/00016480903071377. [ Links ]

73. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010; 6: 15, doi: 10.1186/1746-160X-6-15. [ Links ]

74. Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 2008; 41: 673-695, doi: 10.1016/j.otc.2008.01.016. [ Links ]

75. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917, doi: 10.1002/ijc.25516. [ Links ]

76. Duray A, Descamps G, Arafa M, Decaestecker C, Remmelink M, Sirtaine N, et al. High incidence of high-risk HPV in benign and malignant lesions of the larynx. Int J Oncol 2011; 39: 51-59. [ Links ]

77. Baumann JL, Cohen S, Evjen AN, Law JH, Vadivelu S, Attia A, et al. Human papillomavirus in early laryngeal carcinoma. Laryngoscope 2009; 119: 1531-1537, doi: 10.1002/lary.20509. [ Links ]

78. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783, doi: 10.1093/jnci/djg107. [ Links ]

79. Kaminagakura E, Villa LL, Andreoli MA, Sobrinho JS, Vartanian JG, Soares FA, et al. High-risk human papillomavirus in oral squamous cell carcinoma of young patients. Int J Cancer 2012; 130: 1726-1732, doi: 10.1002/ijc.26185. [ Links ]

80. Miguel RE, Villa LL, Cordeiro AC, Prado JC, Sobrinho JS, Kowalski LP. Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Am J Surg 1998; 176: 428-429, doi: 10.1016/S0002-9610(98)00246-3. [ Links ]

81. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010; 70: 3159-3169, doi: 10.1158/0008-5472.CAN-09-4179. [ Links ]

82. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120: 1763-1768, doi: 10.1002/ijc.22481. [ Links ]

83. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720, doi: 10.1093/jnci/92.9.709. [ Links ]

84. Boscolo-Rizzo P, Da Mosto MC, Fuson R, Frayle-Salamanca H, Trevisan R, Del Mistro A. HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract. J Cancer Res Clin Oncol 2009; 135: 559-566, doi: 10.1007/s00432-008-0490-3. [ Links ]

85. Du J, Nordfors C, Nasman A, Sobkowiak M, Romanitan M, Dalianis T, et al. Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden. PLoS One 2012; 7: e36239, doi: 10.1371/journal.pone.0036239. [ Links ]

86. Syrjanen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010; 21 (Suppl 7): vii243-vii245, doi: 10.1093/annonc/mdq454. [ Links ]

87. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35, doi: 10.1056/NEJMoa0912217. [ Links ]

88. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820, doi: 10.1002/ijc.22851. [ Links ]

89. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010; 2: 15, doi: 10.1186/1758-3284-2-15. [ Links ]

90. Hong AM, Martin A, Armstrong BK, Lee CS, Jones D, Chatfield MD, et al. Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 2013; 24: 215-219, doi: 10.1093/annonc/mds205. [ Links ]

91. Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One 2012; 7: e40767, doi: 10.1371/journal.pone.0040767. [ Links ]

92. Weinberger PM, Merkley MA, Khichi SS, Lee JR, Psyrri A, Jackson LL, et al. Human papillomavirus-active head and neck cancer and ethnic health disparities. Laryngoscope 2010; 120: 1531-1537, doi: 10.1002/lary.20984. [ Links ]

93. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-1998, doi: 10.1200/JCO.2008.20.2853. [ Links ]

94. Hong A, Jones D, Chatfield M, Soon Lee C, Zhang M, Clark J, et al. HPV Status of Oropharyngeal Cancer by Combination HPV-DNA/p16 Testing: Biological Relevance of Discordant Results. Ann Surg Oncol 2012 (Epub 04 December 2012). [ Links ]

95. Villa LL. HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett 2011; 305: 106-112, doi: 10.1016/j.canlet.2010.12.002. [ Links ]

Received: September 20, 2012; Accepted: January 3, 2013

Correspondence: L. Sichero, Laboratório de Biologia Molecular, Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Av. Dr. Arnaldo, 251, 8 o andar, 01246-000 São Paulo, SP, Brasil,

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.